Literature DB >> 29580106

Flagellin as a vaccine adjuvant.

Baofeng Cui1,2, Xinsheng Liu1,2, Yuzhen Fang1,2, Peng Zhou1,2, Yongguang Zhang1,2, Yonglu Wang1,2.   

Abstract

INTRODUCTION: Bacterial flagellin, as a pathogen-associated molecular pattern (PAMP), can activate both innate and adaptive immunity. Its unique structural characteristics endow an effective and flexible adjuvant activity, which allow the design of different types of vaccine strategies to prevent various diseases. This review will discuss recent progress in the mechanism of action of flagellin and its prospects for use as a vaccine adjuvant. AREAS COVERED: Herein we summarize various types of information related to flagellin adjuvants from PubMed, including structures, signaling pathways, natural immunity, and extensive applications in vaccines, and it discusses the immunogenicity, safety, and efficacy of flagellin-adjuvanted vaccines in clinical trials. EXPERT COMMENTARY: It is widely accepted that as an adjuvant, flagellin can induce an enhanced antigen-specific immune response. Flagellin adjuvants will allow more effective flagellin-based vaccines to enter clinical trials. Furthermore, vaccine formulations containing PAMPs are crucial to exert the maximum potential of vaccine antigens. Therefore, combinations of flagellin-adjuvanted vaccines with other adjuvants that act in a synergistic manner, particularly TLR ligands, represent a promising method for tailoring targeted vaccines to meet specific requirements.

Entities:  

Keywords:  Flagellin; NLRC4; TLR5; adjuvant; innate immunity; vaccine

Mesh:

Substances:

Year:  2018        PMID: 29580106     DOI: 10.1080/14760584.2018.1457443

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  32 in total

1.  Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.

Authors:  Eun-Ju Ko; Youri Lee; Young-Tae Lee; Yu-Jin Jung; Vu L Ngo; Min-Chul Kim; Ki-Hye Kim; Bao-Zhong Wang; Andrew T Gewirtz; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-05-14       Impact factor: 3.641

Review 2.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

3.  Manipulation of the silkworm immune system by a metalloprotease from the pathogenic bacterium Pseudomonas aeruginosa.

Authors:  Li Ma; Lizhen Zhou; Jinshui Lin; Jiuyuan Ji; Yang Wang; Haobo Jiang; Xihui Shen; Zhiqiang Lu
Journal:  Dev Comp Immunol       Date:  2018-09-24       Impact factor: 3.636

Review 4.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13

Review 6.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

7.  A multi-epitope vaccine designed against blood-stage of malaria: an immunoinformatic and structural approach.

Authors:  Amir Atapour; Parisa Vosough; Somayeh Jafari; Gholamreza Anani Sarab
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

Review 8.  Factors influencing the immunogenicity of influenza vaccines.

Authors:  Simin Wen; Zhengyu Wu; Shuyi Zhong; Mao Li; Yuelong Shu
Journal:  Hum Vaccin Immunother       Date:  2021-03-11       Impact factor: 3.452

9.  Identification of linear epitopes on the flagellar proteins of Clostridioides difficile.

Authors:  A Razim; K Pacyga; P Naporowski; D Martynowski; A Szuba; A Gamian; S Górska
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 10.  Using PAMPs and DAMPs as adjuvants in cancer vaccines.

Authors:  Huanyou Sun; Wenwen Hu; Yinan Yan; Zichun Zhang; Yuxin Chen; Xuefan Yao; Ling Teng; Xinyuan Wang; Dafei Chai; Junnian Zheng; Gang Wang
Journal:  Hum Vaccin Immunother       Date:  2021-09-14       Impact factor: 4.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.